KRAS gene amplification is a distinct molecular subgroup of gastroesophageal adenocarcinoma that may benefit from combined RAS/RAF/MEK/ERK and PI3K/PTEN/AKT/mTOR pathway inhibition

被引：0
|
作者：
Henderson, Les [1 ]
Xu, Peng [1 ]
Rambo, Brittany [1 ]
Liao, Wei-Li [2 ]
Hembrough, Todd [2 ]
Catenacci, Daniel [1 ]
机构：
[1] Univ Chicago Med, Chicago, IL USA
[2] Oncoplex Dx Inc, Rockville, MD USA
来源：
MOLECULAR CANCER RESEARCH | 2014年 / 12卷
关键词：
D O I：
10.1158/1557-3125.RASONC14-A55
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A55
引用
收藏
页数：2
相关论文
共 37 条
  • [31] miR-34a/c induce caprine endometrial epithelial cell apoptosis by regulating circ-8073/CEP55 via the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways
    Liu, Xiaorui
    Zhang, Lei
    Yang, Lichun
    Cui, Jiuzeng
    Che, Sicheng
    Liu, Yuexia
    Han, Jincheng
    An, Xiaopeng
    Cao, Binyun
    Song, Yuxuan
    JOURNAL OF CELLULAR PHYSIOLOGY, 2020, 235 (12) : 10051 - 10067
  • [32] Tanshinone IIA can decrease growth factor receptors expression and dural-block both Ras/Raf/MEK/ERK and Ras/PI3K/Akt/mTOR pathways to inhibit human breast cancer BT-20 cells
    Su, Chin Cheng
    CANCER RESEARCH, 2017, 77
  • [33] Inactivation of PI3K/Akt pathway and upregulation of PTEN gene are involved in daucosterol, isolated from Salvia sahendica, induced apoptosis in human breast adenocarcinoma cells
    Esmaeili, Mohammad Ali
    Farimani, Mahdi Moridi
    SOUTH AFRICAN JOURNAL OF BOTANY, 2014, 93 : 37 - 47
  • [34] Dual targeting of RAF-MEK-ERK and PI3K-AKT-mTOR pathways in RAS-mutant cancers: Preclinical and institutional experience from a clinical trial of binimetinib (MEK162) plus BYL719.
    Banerji, Udai
    Smith, Alan David
    Zivi, Andrea
    Lorente, David
    Rihawi, Karim
    Tunarlu, Nina
    Stewart, Adam
    Thavasu, Parames
    Kaag, Audrey
    Radhakrishnan, Rajkumar
    Maacke, Heiko
    Molife, L. Rhoda
    Kaye, Stanley B.
    Do Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] Sub-group of HER2-negative breast cancer patients with hyperactive RAS network signaling identified: Dynamic pathway activity test identifies patients that may benefit from PI3K/mTOR or PI3K/mTOR/BCL inhibitors.
    Khan, Salmaan
    Sen, Adrish
    Kuzmicki, Catherine
    MacNeil, Ian
    Broege, Aaron
    Mutka, Sarah
    Brass, Kelly
    McCracken, Ky
    Milligan, Laura
    Kotke, Katja
    Sullivan, Brian
    Laing, Lance
    CANCER RESEARCH, 2021, 81 (13)
  • [36] Oncogenic mutant KRAS modulates EZH2 expression through MEK-ERK and PI3K/AKT signaling in NSCLC: differential effects of different KRAS mutations and increased efficacy of inhibition combined with EZH2 targeted therapy
    Riquelme, Erick M.
    Shen, Li
    Wang, Jing
    Behrens, Carmen
    Simon, George
    Papadimitrakopoulou, Vassiliki
    Minna, John D.
    Wistuba, Ignacio I.
    CANCER RESEARCH, 2015, 75
  • [37] Carcinoma of the ampulla of Vater with CIMP plus after treatment with pegylated liposomal based formulation of Ras siRNA combined with vinorelbine-tartrate exhibited inhibition of Raf/MEK/ERK, PI3K/AKT, DNA methylation and re-expression of tumor suppressor genes inducing type I, II, IIIPCD
    Giannios, J.
    Lambrinos, P.
    Alexandropulos, N.
    Ginopulos, P.
    EJC SUPPLEMENTS, 2006, 4 (12): : 105 - 106
1234